lexatumumab

{
  "id": "MLC-T-ONC-004813",
  "term": "lexatumumab",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A substance being studied in the treatment of some types of cancer. It binds to a protein called TRAIL-R2 on the surface of some tumor cells, which may kill the tumor cells. Lexatumumab is a type of monoclonal antibody. Also called anti-TRAIL R2 mAb HGS-ETR2 and HGS-ETR2.",
    "A fully human monoclonal agonistic antibody directed against tumor necrosis factor-alpha (TNF-alpha)-related apoptosis-inducing ligand receptor-2 (TRAIL-R2) with potential antitumor activity. Mimicking the natural ligand TRAIL, lexatumumab binds to and activates TRAIL-R2, which may trigger apoptosis in and inhibit the growth of TRAIL-R2-expressing tumor cells. TRAIL-R2, also known as death receptor 5 (DR5), is a member of the TNF receptor family and is expressed on many malignant cell types."
  ],
  "synonyms": [
    "anti-TRAIL R2 mAb HGS-ETR2",
    "HGS-ETR2",
    "monoclonal antibody HGS-ETR2",
    "anti-TRAIL receptor 2 monoclonal antibody HGS-ETR2"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/lexatumumab/"
}